F S&P 500
5,207.25 -5.50 (-0.11%) F Dow Jones
39,161.00 -34.00 (-0.09%) F Nasdaq
18,155.75 -30.75 (-0.17%) E-mini Russell 2000 Index Futur
2,059.90 -4.90 (-0.24%) Petróleo
79.42 +0.43 (+0.54%) Oro
2,320.80 -1.50 (-0.06%)
Ventana Biotech, Inc. (VNTA)
Ventana Biotech, Inc.
1 Bachstrasse
Butschwil 9606
Switzerland
41 44 732 60 59
Sector(es): Financial Services
Industria: Shell Companies
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Janne Christensen | Chief Exec. Officer, Pres, Chief Financial Officer, Treasurer and Director | N/D | N/D | N/D |
| Mr. David Holsworth | Chief Operating Officer, VP and Exec. Director | N/D | N/D | N/D |
| Ms. Marilyn Thom | VP of Admin. & HR | N/D | N/D | N/D |
| Mr. Elliott Martin | VP of Sales and Marketing | N/D | N/D | N/D |
| Mr. Trevor Conn | Exec. Director | N/D | N/D | N/D |
| Mr. Yoon Youngkeun | Sec. and Director | N/D | N/D | N/D |
Descripción
Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. The company focuses in the areas of anti-obesity and related illnesses. The company holds rights for the formula for a medicament containing chewing gum with a composition of the extract of hoodia gordonii and 2-hydroxyoleic acid for the treatment of obesity, hypertension, and other metabolic disorders. The company develops appetite suppressant chewing gums, including the low dosage product for the over-the-counter market and the high dosage product for distribution by pharmacists. It intends to market low dosage product though drug and health food stores. The company was formerly known as Personalica, Inc. and changed its name to Ventana Biotech, Inc. in October 2008. Ventana Biotech, Inc. was founded in 1989 and is based in Butschwil, Switzerland.
Gestión corporativa
La calificación ISS Governance QuickScore de Ventana Biotech, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
